ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Unfortunately, mutations rendering CML patients non-responsive to TKIs have been identified, including the threonine 315 to isoleucine (T315I) mutation and several others, which prevent binding of different TKIs to the active site of the ABL kinase, thereby avoiding its inhibition [85,86].